These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 29048260)

  • 21. Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis.
    Watts NB; Hattersley G; Fitzpatrick LA; Wang Y; Williams GC; Miller PD; Cosman F
    Osteoporos Int; 2019 Jun; 30(6):1187-1194. PubMed ID: 30899994
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of Abaloparatide on Bone Mineral Density in Proximal Femoral Regions Corresponding to Arthroplasty Gruen Zones: A Study of Postmenopausal Women with Osteoporosis.
    Sheth NP; Smith JR; Winzenrieth R; Humbert L; Wang Y; Boxberger JI; Bostrom MP
    J Bone Joint Surg Am; 2024 Jul; 106(13):1162-1170. PubMed ID: 38691582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abaloparatide: Review of a Next-Generation Parathyroid Hormone Agonist.
    Boyce EG; Mai Y; Pham C
    Ann Pharmacother; 2018 May; 52(5):462-472. PubMed ID: 29241341
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Abaloparatide: First Global Approval.
    Shirley M
    Drugs; 2017 Aug; 77(12):1363-1368. PubMed ID: 28624872
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Abaloparatide Increases Lumbar Spine and Hip BMD in Japanese Patients With Osteoporosis: The Phase 3 ACTIVE-J Study.
    Matsumoto T; Sone T; Soen S; Tanaka S; Yamashita A; Inoue T
    J Clin Endocrinol Metab; 2022 Sep; 107(10):e4222-e4231. PubMed ID: 35977548
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial.
    Leder BZ; Zapalowski C; Hu MY; Hattersley G; Lane NE; Singer AJ; Dore RK
    J Bone Miner Res; 2019 Dec; 34(12):2213-2219. PubMed ID: 31411768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Parathyroid Hormone and Parathyroid Hormone-Related Protein Analogs in Osteoporosis Therapy.
    Leder BZ
    Curr Osteoporos Rep; 2017 Apr; 15(2):110-119. PubMed ID: 28303448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abaloparatide: A review of preclinical and clinical studies.
    Brent MB
    Eur J Pharmacol; 2021 Oct; 909():174409. PubMed ID: 34364879
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial.
    Cosman F; Miller PD; Williams GC; Hattersley G; Hu MY; Valter I; Fitzpatrick LA; Riis BJ; Christiansen C; Bilezikian JP; Black D
    Mayo Clin Proc; 2017 Feb; 92(2):200-210. PubMed ID: 28160873
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Abaloparatide and the Spine: A Narrative Review.
    Thompson JC; Wanderman N; Anderson PA; Freedman BA
    Clin Interv Aging; 2020; 15():1023-1033. PubMed ID: 32636617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial.
    Bilezikian JP; Hattersley G; Mitlak BH; Hu MY; Fitzpatrick LA; Dabrowski C; Miller PD; Papapoulos SE
    Curr Med Res Opin; 2019 Dec; 35(12):2097-2102. PubMed ID: 31418585
    [No Abstract]   [Full Text] [Related]  

  • 32. Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide.
    McClung MR; Williams GC; Hattersley G; Fitzpatrick LA; Wang Y; Miller PD
    Calcif Tissue Int; 2018 Jun; 102(6):627-633. PubMed ID: 29285549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of a sequential treatment combining abaloparatide and alendronate for the management of postmenopausal osteoporosis.
    Reginster JY; Al Daghri N; Kaufman JM; Bruyère O
    Expert Opin Pharmacother; 2018 Feb; 19(2):159-161. PubMed ID: 29251010
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial.
    Miller PD; Hattersley G; Lau E; Fitzpatrick LA; Harris AG; Williams GC; Hu MY; Riis BJ; Russo L; Christiansen C
    Bone; 2019 Mar; 120():137-140. PubMed ID: 30359763
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase 1b Evaluation of Abaloparatide Solid Microstructured Transdermal System (Abaloparatide-sMTS) in Postmenopausal Women with Low Bone Mineral Density.
    Miller PD; Troy S; Weiss RJ; Annett M; Schense J; Williams SA; Mitlak B
    Clin Drug Investig; 2021 Mar; 41(3):277-285. PubMed ID: 33638863
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Osteoanabolic and dual action drugs.
    Tabacco G; Bilezikian JP
    Br J Clin Pharmacol; 2019 Jun; 85(6):1084-1094. PubMed ID: 30218587
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Six Weeks of Daily Abaloparatide Treatment Increased Vertebral and Femoral Bone Mineral Density, Microarchitecture and Strength in Ovariectomized Osteopenic Rats.
    Bahar H; Gallacher K; Downall J; Nelson CA; Shomali M; Hattersley G
    Calcif Tissue Int; 2016 Nov; 99(5):489-499. PubMed ID: 27395059
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Romosozumab versus parathyroid hormone receptor agonists: which osteoanabolic to choose and when?
    Anastasilakis AD; Yavropoulou MP; Palermo A; Makras P; Paccou J; Tabacco G; Naciu AM; Tsourdi E
    Eur J Endocrinol; 2024 Jul; 191(1):R9-R21. PubMed ID: 38938063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Abaloparatide Exerts Bone Anabolic Effects with Less Stimulation of Bone Resorption-Related Factors: A Comparison with Teriparatide.
    Makino A; Takagi H; Takahashi Y; Hase N; Sugiyama H; Yamana K; Kobayashi T
    Calcif Tissue Int; 2018 Sep; 103(3):289-297. PubMed ID: 29725706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abaloparatide versus teriparatide: a head to head comparison of effects on fracture healing in mouse models.
    Bernhardsson M; Aspenberg P
    Acta Orthop; 2018 Dec; 89(6):674-677. PubMed ID: 30334479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.